Pasireotide
Multi-ligand somatostatin analog for Cushing’s disease. Broad somatostatin receptor binding profile with enhanced SSTR5 affinity for ACTH suppression in pituitary disorders.
Pasireotide is a novel cyclohexapeptide somatostatin analog with high-affinity binding to somatostatin receptor subtypes SSTR1, SSTR2, SSTR3, and SSTR5. It is approved for the treatment of Cushing’s disease and acromegaly, offering broader receptor coverage than first-generation somatostatin analogs, resulting in superior efficacy in controlling cortisol and growth hormone excess.
| Parameter | Specification |
| CAS | 396091-73-9 |
| Molecular Formula | C₅₈H₆₆N₁₀O₉ |
| Molecular Weight | 1047.21 g/mol |
| Category | Oncology/Endocrine |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Cushing’s disease, acromegaly, neuroendocrine tumors |
| CAS | 396091-73-9 |
|---|---|
| Applications | Acromegaly, Multi-ligand somatostatin analog (SSTR1/2/3/5 agonist), Neuroendocrine Tumors (NETs) |
Related products
-
Teduglutide
CAS: 197922-42-2Applications: Crohn Disease, GLP-2, Intestinal Repair, Short Bowel Syndrome -
Dulaglutide
CAS: 923950-08-7 -
Glucagon HCl
CAS: 16941-32-5Applications: Diabetic Emergency, Glycogenolysis, Hypoglycemia Rescue -
Exenatide Acetate
CAS: 141732-76-5Applications: GLP-1, obesity management, Type 2 diabetes